We then applied this signature in STEP 2, an external validation set, in which it showed similar performance for distinguishing semaglutide treatment from placebo (AUC = 0.93) (Extended Data Fig
10.1016/j.cell.2014.10.039 64 KerstanA.DieterK.Niebergall-RothE.DachtlerA
[DOI] [PMC free article] [PubMed] [Google Scholar] 105.Barisic I., Balenovic D., Klicek R., Radic B., Nikitovic B., Drmic D., Udovicic M., Strinic D., Bardak D., Berkopic L., et al
Systematic, cell-typerestricted perturbations in human tumorsideally during therapyare needed to adjudicate these models and to avoid off-target immunologic liabilities as reader inhibitors enter development (156)
High-density mapping of the MHC identifies a shared role for HLA-DRB1*01:03 in inflammatory bowel diseases and heterozygous advantage in ulcerative colitis
Quick Physician Visit and Fast Delivery